![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260917_Bayer_Therapeutic_Indications-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Bayer<\/p>\n Event Type<\/strong><\/p>\n FDA Approval (Indication Expansion)<\/p>\n Modality<\/strong><\/p>\n Selective Non-Steroidal Mineralocorticoid-Receptor Antagonist<\/p>\n Asset<\/strong><\/p>\n Finerenone (Kerendia)<\/p>\n Disease Area<\/strong><\/p>\n Chronic Kidney Disease Associated With Type 1 Diabetes<\/p>\n FDA approved finerenone (Kerendia) to reduce urine albumin-to-creatinine ratio in adults with chronic kidney disease associated with type 1 diabetes. Bayer describes this as the first FDA-approved treatment option in more than 30 years for this population. The decision broadens finerenone beyond type 2 diabetes and heart failure, but the labeled claim is based on a validated surrogate rather than direct renal-outcome evidence in type 1 diabetes.<\/p>\n The approval was announced September 17, 2026 after Priority Review. In the randomized, double-blind 242-participant Phase III FINE-ONE study, finerenone added to standard care reduced UACR by 25% over six months versus placebo. At any post-baseline assessment, 68.1% of finerenone-treated participants and 46.6% of placebo participants achieved at least a 30% UACR reduction. FDA authorized use to reduce UACR, which is expected to reduce the risk of sustained eGFR decline and end-stage kidney disease. The label therefore does not state that FINE-ONE directly demonstrated fewer kidney-failure events.<\/p>\n The strongest interpretation is that finerenone extends mineralocorticoid-receptor blockade into an underserved type 1 diabetes population with biologically consistent albuminuria reduction and a safety profile broadly aligned with the established type 2 diabetes experience. The competing interpretation is that surrogate transfer across diabetes types may not fully capture long-term renal benefit, while hyperkalemia and monitoring requirements may constrain use. The regulatory bridge relies partly on prior finerenone outcome studies and the relationship between albuminuria reduction and kidney protection. Confirmation will require longer follow-up, real-world renal outcomes and evidence on use alongside evolving glucose, blood-pressure and renoprotective standards.<\/p>\n CKD in type 1 diabetes reflects metabolic, hemodynamic, inflammatory and fibrotic injury and is often first detected through rising albuminuria. Finerenone blocks mineralocorticoid-receptor overactivation and is already approved in the United States for CKD associated with type 2 diabetes and for symptomatic heart failure with left-ventricular ejection fraction of at least 40%.<\/p>\n The approval is a meaningful positive signal for label expansion and for surrogate-supported renal drug development, but it should not be described as a direct kidney-outcome win in type 1 diabetes. The commercial and clinical question is whether physicians adopt finerenone broadly enough, with manageable potassium monitoring, to convert the first dedicated label into durable standard-of-care use.<\/p>\n Signal strength:<\/strong> 5\/5. Importance:<\/strong> Positive. Confidence:<\/strong> High on facts; moderate on interpretation.<\/p>\n","protected":false},"excerpt":{"rendered":" FDA approved finerenone (Kerendia) to reduce urine albumin-to-creatinine ratio in adults with chronic kidney disease associated with type 1 diabetes. Bayer describes this as the first FDA-approved treatment option in more than 30 years…<\/p>\n","protected":false},"author":1,"featured_media":3291,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[800,146,801],"class_list":["post-3258","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-bayer","tag-chronic-kidney-disease","tag-type-1-diabetes"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3258"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3258\/revisions"}],"predecessor-version":[{"id":3294,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3258\/revisions\/3294"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3291"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n